6.
Perry J, Osman S, Wright J, Richard-Greenblatt M, Buchan S, Sadarangani M
. Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS One. 2022; 17(4):e0266852.
PMC: 8993021.
DOI: 10.1371/journal.pone.0266852.
View
7.
B Gilbert P, Montefiori D, McDermott A, Fong Y, Benkeser D, Deng W
. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021; 375(6576):43-50.
PMC: 9017870.
DOI: 10.1126/science.abm3425.
View
8.
H Mulholland R, Vasileiou E, Simpson C, Robertson C, Ritchie L, Agrawal U
. Cohort Profile: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) Database. Int J Epidemiol. 2021; 50(4):1064-1074.
PMC: 8195245.
DOI: 10.1093/ije/dyab028.
View
9.
Clift A, Coupland C, Keogh R, Diaz-Ordaz K, Williamson E, Harrison E
. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020; 371:m3731.
PMC: 7574532.
DOI: 10.1136/bmj.m3731.
View
10.
Asif S, Frithiof R, Lipcsey M, Kristensen B, Alving K, Hultstrom M
. Weak anti-SARS-CoV-2 antibody response is associated with mortality in a Swedish cohort of COVID-19 patients in critical care. Crit Care. 2020; 24(1):639.
PMC: 7645408.
DOI: 10.1186/s13054-020-03362-y.
View
11.
Palmateer N, Dickson E, Furrie E, Godber I, Goldberg D, Gousias P
. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic. Public Health. 2021; 198:102-105.
PMC: 8289625.
DOI: 10.1016/j.puhe.2021.07.006.
View
12.
Dimeglio C, Migueres M, Bouzid N, Chapuy-Regaud S, Gernigon C, Da-Silva I
. Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection. Vaccines (Basel). 2022; 10(9).
PMC: 9506424.
DOI: 10.3390/vaccines10091548.
View
13.
Notarte K, Ver A, Velasco J, Pastrana A, Catahay J, Salvagno G
. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit Rev Clin Lab Sci. 2022; 59(6):373-390.
PMC: 8935447.
DOI: 10.1080/10408363.2022.2038539.
View
14.
Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S
. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(11):2032-2040.
PMC: 8604724.
DOI: 10.1038/s41591-021-01540-1.
View
15.
Martin-Vicente M, Almansa R, Martinez I, Tedim A, Bustamante E, Tamayo L
. Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. J Intern Med. 2021; 291(2):232-240.
PMC: 8661581.
DOI: 10.1111/joim.13386.
View
16.
Florentino P, Millington T, Cerqueira-Silva T, Robertson C, Oliveira V, Junior J
. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. Lancet Infect Dis. 2022; 22(11):1577-1586.
PMC: 9359673.
DOI: 10.1016/S1473-3099(22)00451-0.
View
17.
Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S
. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 2021; 11(7):136.
PMC: 8323747.
DOI: 10.1038/s41408-021-00528-x.
View
18.
Schinas G, Polyzou E, Mitropetrou F, Pazionis A, Gogos C, Triantos C
. COVID-19 Vaccination in Patients with Chronic Liver Disease. Viruses. 2022; 14(12).
PMC: 9785164.
DOI: 10.3390/v14122778.
View
19.
Kara Z, Akcin R, Demir A, Oyku Dinc H, Taskin H, Kocazeybek B
. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity. Obes Surg. 2022; 32(9):2987-2993.
PMC: 9263798.
DOI: 10.1007/s11695-022-06181-y.
View
20.
Ward H, Whitaker M, Flower B, Tang S, Atchison C, Darzi A
. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022; 13(1):907.
PMC: 8850615.
DOI: 10.1038/s41467-022-28527-x.
View